Dr Reddy's Laboratories (DRREDDY) Weekly Analysis
Price & Volume
This week, the stock price saw a decline of 2.69%, closing at 1210.8. The trading range was 2.92%, indicating a moderate week. Trading volume was significantly lower than the previous week, down by 50.15%. The stock price closed below its 50-day and 200-day moving averages.
Technicals
This week, the stock closed down 2.7%, trading below its 20-week and 50-week moving averages (MAs). The Relative Strength Index (RSI), a measure of overbought or oversold conditions, fell to 31.8, indicating weakening momentum. The MACD histogram, showing the difference between two MACD lines, also declined sharply. Bollinger Band width increased, suggesting rising volatility. Overall, the technical picture shows a downtrend with weakening momentum and increasing volatility.
Fundamentals
Dr Reddy's Laboratories' recent performance shows a significant decline in revenue and net profit. In Mar 2026, revenue decreased by 11.5% YoY and net profit by 86.1% YoY. The operating margin for the quarter was 5.0%. The company's valuation currently stands at 33.0x Price-to-Earnings (PE) and 3.2x Price-to-Book (PB). These figures indicate a challenging near-term financial environment.
News
On July 15, 2026, Dr. Reddy's Laboratories announced a halt in semaglutide supplies due to an impurity issue, impacting its product availability. The company is scheduled to release its Q1 FY27 results on July 22, 2026. Additionally, on July 15, 2026, HSBC Holdings PLC sold 111,151 shares of Dr. Reddy's Laboratories. MarketBeat reported on July 16, 2026, that the company's quarterly earnings were projected for release on Wednesday, July 17, 2026. These events occurred within the reporting window of July 13 to July 17, 2026.
Events
Dr. Reddy's Laboratories announced a transcript of a conference call regarding a scale-up issue with Semaglutide API manufacturing, which led to a temporary halt in commercial supplies. The company is investigating the root cause and expects to resume supplies by late October or early November.
Dr. Reddy's Laboratories will announce its Q1FY27 financial results on July 22, 2026, followed by an earnings call to discuss performance. Shareholders can expect details on the company's financial health for the quarter.
Dr. Reddy's Laboratories has announced the audio recording of their conference call held on July 9, 2026, is now available. This provides shareholders with access to discussions regarding the company's performance and strategy.
Dr. Reddy's Laboratories announced a delay in semaglutide supplies due to an API issue, with no impact on patient safety. The company will host a conference call to discuss the matter.
Dr. Reddy's Laboratories announced that certain batches of semaglutide are out of specification due to an API issue, leading to delayed commercial supplies. The company is investigating the root cause and will host a conference call to discuss the matter.
The provided audio content is a recording of a concall from July 2026. It contains technical audio data and does not include discernible business or financial information relevant to shareholders.
Dr. Reddy's Laboratories will announce its Q1FY27 financial results on July 22, 2026, followed by an earnings call to discuss performance. Shareholders can expect details on the company's financial health for the quarter.
Dr. Reddy's Laboratories has announced the audio recording of their conference call held on July 9, 2026, is now available. This provides shareholders with access to discussions regarding the company's performance and strategy.
Dr. Reddy's Laboratories announced a delay in semaglutide supplies due to an API issue, with no impact on patient safety. The company will host a conference call to discuss the matter.
Dr. Reddy's Laboratories announced that certain batches of semaglutide are out of specification due to an API issue, leading to delayed commercial supplies. The company is investigating the root cause and will host a conference call to discuss the matter.
The provided audio content is a recording of a concall from July 2026. It contains technical audio data and does not include discernible business or financial information relevant to shareholders.
Weekly Snapshot
Highlights
- The stock declined 2.69% this week, closing at 1210.8, driven by a significant drop in trading volume and continued bearish technical indicators.
- Dr. Reddy's Laboratories announced a halt in semaglutide supplies due to an impurity issue, impacting product availability and leading to a delay in commercial supplies.
- Trading volume decreased by 50.15% compared to the previous week, indicating reduced investor interest amidst a downward price trend.
- Technical indicators show a downtrend with weakening momentum, as the stock is trading below its 50-day and 200-day moving averages, and the RSI has fallen to 31.8.
- The company is scheduled to announce its Q1 FY27 results on July 22, 2026, with an earnings call.
What This Means
Dr. Reddy's Laboratories experienced a challenging week with a price decline and significantly lower trading volume. The company announced a halt in semaglutide supplies due to an impurity issue, which is a key concern for product availability. While the stock's technicals indicate a bearish trend, upcoming Q1 FY27 results will be crucial for understanding the company's financial performance and outlook.
Latest Quarter Info
The latest quarterly snapshot for March 2026 indicates a mixed performance. Revenue experienced a sequential decline of 13.8% and a year-over-year decrease of 11.5%. Profitability trends show a significant contraction, with net profit dropping 81.4% quarter-over-quarter and 86.1% year-over-year. Operating margin remained stable at 5.0%. The mix of QoQ and YoY signals suggests a challenging period, with both short-term and long-term revenue momentum negative. The substantial drop in net profit and EPS across both metrics warrants attention, despite the stable operating margin. This quarter's results present a complex picture of revenue contraction coupled with a severe decline in bottom-line profitability.